Affiliation:
1. National Medical Research Centre for Oncology
2. National Medical Research Centre for Oncology; Rostov State Medical University
3. Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1
Abstract
Purpose of the study. The purpose of the study was to analyze parameters of molecular markers of structural and cellular renal damage in localized renal cell carcinoma (RCC) with determining the nature of the initial abnormalities in the kidney functional state before the treatment.Patients and methods. The study included 46 patients receiving elective surgical treatment for localized renal cancer in the Department of Oncourology, National Medical Research Centre for Oncology. The comparison group included the clinical and laboratory data of 13 healthy people comparable with the RCC patients in terms of age and gender. Cystatin C, IL‑18, KIM‑1, L-FABP, NGAL were determined in blood and urine in all patients.Results. Evaluation of the kidney functional state of RCC patients showed that the initial values of serum creatinine and the glomerular filtration rate were similar to the reference levels in healthy people, but statistically significant differences were found in the ratios of cystatin C concentrations in the blood and urine in all patients, compared with normal values. Determination of L-FABP indices in RCC patients showed that their levels were 2.5 times higher than normal values, and the urine concentration of IL‑18 was 1.7 times higher than normal values (p < 0.05). Blood and urine levels of NGAL and KIM‑1 did not differ significantly from the comparison group.Conclusions. The development of localized RCC is accompanied by the formation of tubulointerstitial dysfunction with impaired renal filtration capacity. All RCC patients showed elevated endogenous markers of structural and cellular renal damage – cystatin C, L-FABP, and IL‑18.
Publisher
ANO -Perspective of Oncology
Reference26 articles.
1. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by Kaprina AD, Starinskiy VV, Shakhzadovo AO. P. A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Moscow: 2020, 252 p. (In Russ.).
2. Axel EM, Matveev VB. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Cancer Urology. 2019;15(2):15–24. (In Russ.). https://doi.org/10.17650/1726-9776-2019-15-2-15-24
3. Rakul SA, Pozdnyakov KV, Eloev RA, Pliskachevskiy NA. Practical aspects of treatment of kidney cancer in a modern hospital: the evolution of surgical approaches. Cancer Urology. 2018;14(2):44–53. (In Russ.). https://doi.org/10.17650/1726-9776-2018-14-2-44--53
4. Kit OI, Frantsiyants EM, Dimitriadi SN, Shevchenko AN, Kaplieva IV, Tripitaki LK. The expression of markers of neoangiogenesis and fibrinolytic system in dynamics of experimental renal ischemia in rats. Experimental and Clinical Urology. 2015;1:20–23. (In Russ.).
5. Ostermann M. Acute kidney injury during critical illness – a global challenge. Messenger of Anesthesiology and Resuscitation. 2019;16(2):83–95. https://doi.org/0.21292/2078-5658-2019-16-2-83-95